The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Effects of Fibrinogen Concentrate as First-line Therapy during Major Aortic Replacement Surgery: A Randomized, Placebo-controlled Trial
Open accessAbstract
Major bleeding during complex surgery increases the need for blood transfusions, prolongs the patient’s stay in the intensive care unit (ICU), and is associated with increased morbidity and mortality.1,2The standard treatment of perioperative bleeding involves the transfusion of allogeneic blood components (erythrocytes, fresh frozen plasma [FFP], platelet concentrate, or cryoprecipitate). Although these components have become safer, there is evidence that the transfusion of allogeneic blood components may be associated with a risk of serious adverse events.3–5Thus, treatment approaches that can reduce transfusion appear desirable.Clot strength increases with increasing concentrations of fibrinogen, and fibrinogen levels higher than 200 mg/dl have been suggested for optimal clot formation.6–8Immediately after cardiopulmonary bypass (CPB), fibrin formation is impaired to a greater extent than either thrombin generation or the platelet component of clot strength.9The plasma concentration of fibrinogen10,11and the firmness (elasticity/strength) of the fibrin-based clot9have been reported to decrease by an average of 34–42% in response to CPB. Furthermore, low levels of fibrinogen are associated with an increased risk of postoperative bleeding.10,12,13Overall, there is considerable evidence to support fibrinogen supplementation as a first-line treatment for coagulopathic bleeding among patients undergoing CPB. Several studies have suggested that fibrinogen concentrate therapy may be effective in controlling perioperative bleeding, reducing transfusion requirements as well as blood loss.11,14–19Fibrinogen concentrate is derived from human plasma and does not contain relevant levels of other coagulation factors.20Our group has developed and validated a model for individualized dosing of fibrinogen concentrate,17,18by measuring firmness of the fibrin-based clot, which is mainly dependent on plasma fibrinogen levels.13,21,22Maximum clot firmness (MCF) of the fibrin-based clot can be monitored using a commercially available fibrin-based thromboelastometry test (FIBTEM).11,23A clinical study is needed to investigate the efficacy and safety of fibrinogen concentrate in managing severe perioperative bleeding. We hypothesized that fibrinogen concentrate can reduce the need for blood transfusions without increasing the rate of serious adverse events when given intraoperatively as individualized first-line hemostatic therapy in bleeding patients undergoing aortic replacement surgery.This phase 2, prospective, randomized, double-blind, placebo-controlled, parallel-group, stratified, clinical study was conducted at a single center (Hannover Medical School, Hannover, Germany). It was approved by the Local Ethics Committee in Hannover, Germany, and by the German Regulatory Authorities; it was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice. The study was assigned Local Ethics Committee reference code no. 4891M-mono, EudraCT trial no. 2007-004612-31, and ClinicalTrials.govidentifier no. NCT00701142.Patients aged 18 yr or older for whom elective aortic replacement surgery involving CPB was planned and who provided signed informed consent were enrolled between June 2008 and April 2010. All aortic valve operations with root/ascending aorta replacement (thoracic aortic aneurysm [TAA]), with or without aortic arch replacement, and thoracoabdominal replacements were eligible. Patients were excluded from the study if they had undergone previous surgery at the same aortic site, if they had a congenital or acquired coagulation disorder, if they had a myocardial infarction or stroke in the previous 2 months, or if they used aspirin, clopidogrel, or vitamin K antagonists in the previous 2–5 days. All patients received antifibrinolytic prophylaxis with tranexamic acid (30 mg/kg bodyweight as a preoperative loading dose, followed by 1 mg/kg bodyweight/h throughout surgery). CPB was established after aortic cannulation and administration of 400 IU/kg heparin (Heparin-Natrium-25000-ratiopharm®; Merckle GmbH, Blaubeuren, Germany).Before surgery, patients were randomized to receive either fibrinogen concentrate or placebo; study medication was administered if clinically relevant bleeding occurred. This was defined as a 5-min bleeding mass of 60–250 g immediately after removal from CPB, neutralization of heparin with protamine sulfate (Protamin Valeant, Valeant Pharmaceuticals GmbH, Eschborn, Germany; protamine–heparin ratio of 1:1), and completion of surgical hemostasis, which includes suture placement and electrocautery (or diathermy) (fig. 1). Completion of surgical hemostasis consisted of surgical control of focal bleeding. Surgical hemostasis was deemed to be complete if no obvious sources of bleeding were identified. A 5-min bleeding mass was subsequently determined by weighing dry surgical cloths and compresses, applying them to the surgical area for 5 min and weighing them again. No irrigation of the
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Murphy, G. J., Reeves, B. C., Rogers, C. A., Rizvi, S. I. A., Culliford, L., & Angelini, G. D. (2007) · Circulation · doi:10.1161/circulationaha.107.698977 · Cited by 1,371
Management of bleeding following major trauma: an updated European guideline
Rossaint, R., Bouillon, B., Cerny, V., Coats, T. J., Duranteau, J., Fernández-Mondéjar, E., Hunt, B. J., Komadina, R., Nardi, G., Neugebauer, E., et al. (2010) · Critical Care · doi:10.1186/cc8943 · Cited by 818
Prevention and Treatment of Major Blood Loss
Mannucci, P. M., & Levi, M. (2007) · New England Journal of Medicine · doi:10.1056/nejmra067742 · Cited by 494
Diagnosis of early coagulation abnormalities in trauma patients by rotation thrombelastography
RUGERI, L., LEVRAT, A., DAVID, J. S., DELECROIX, E., FLOCCARD, B., GROS, A., ALLAOUCHICHE, B., & NEGRIER, C. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02319.x · Cited by 491
Görlinger, K., Dirkmann, D., Hanke, A. A., Kamler, M., Kottenberg, E., Thielmann, M., Jakob, H., & Peters, J. (2011) · Anesthesiology · doi:10.1097/aln.0b013e31823497dd · Cited by 426
Self-citationLang, T., Johanning, K., Metzler, H., Piepenbrock, S., Solomon, C., Rahe-Meyer, N., & Tanaka, K. A. (2009) · Anesthesia & Analgesia · doi:10.1213/ane.0b013e3181966675 · Cited by 302
Self-citationCiavarella, D., Reed, R. L., Counts, R. B., Baron, L., Pavlin, E., Heimbach, D. M., & Carrico, C. J. (1987) · British Journal of Haematology · doi:10.1111/j.1365-2141.1987.tb02359.x · Cited by 298
Lowe, G. D. O., Rumley, A., Woodward, M., Morrison, C. E., Philippou, H., Lane, D. A., & Tunstall‐Pedoe, H. (1997) · British Journal of Haematology · doi:10.1046/j.1365-2141.1997.1222936.x · Cited by 281
Fenger-Eriksen, C., Lindberg-Larsen, M., Christensen, A. Q., Ingerslev, J., & Sørensen, B. (2008) · British Journal of Anaesthesia · doi:10.1093/bja/aen270 · Cited by 265
Self-citation
Cited by
Management of severe perioperative bleeding: Guidelines from the European Society of Anaesthesiology
Kozek-Langenecker, S. A., Afshari, A., Albaladejo, P., Santullano, C. A. A., De Robertis, E., Filipescu, D. C., Fries, D., Görlinger, K., Haas, T., Imberger, G., et al. (2013) · European Journal of Anaesthesiology · doi:10.1097/eja.0b013e32835f4d5b · Cited by 909
Self-citation2017 EACTS/EACTA Guidelines on patient blood management for adult cardiac surgery
Pagano, D., Milojevic, M., Meesters, M. I., Benedetto, U., Bolliger, D., von Heymann, C., Jeppsson, A., Koster, A., Osnabrugge, R. L., Ranucci, M., et al. (2018) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezx325 · Cited by 481
2017 EACTS/EACTA Guidelines on patient blood management for adult cardiac surgery
Boer, C., Meesters, M. I., Milojevic, M., Benedetto, U., Bolliger, D., von Heymann, C., Jeppsson, A., Koster, A., Osnabrugge, R. L., Ranucci, M., et al. (2018) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2017.06.026 · Cited by 466
Vlaar, A. P., Oczkowski, S., de Bruin, S., Wijnberge, M., Antonelli, M., Aubron, C., Aries, P., Duranteau, J., Juffermans, N. P., Meier, J., et al. (2020) · Intensive Care Medicine · doi:10.1007/s00134-019-05884-8 · Cited by 284
Alternatives to blood transfusion
Spahn, D. R., & Goodnough, L. T. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60808-9 · Cited by 261
Metadata
- Authors
- Rahe-Meyer, N., Solomon, C., Hanke, A., Schmidt, D. S., Knoerzer, D., Hochleitner, G., Sørensen, B., Hagl, C., & Pichlmaier, M.
- Venue
- Anesthesiology
- Published
- 2013-01-01
- Volume
- 118
- Issue
- 1
- Pages
- 40-50
- ISSN
- 0003-3022 (ISSN-L)
- OpenAlex
- W2013856778
- Cited by
- 274
- References
- 34
- FWCI
- 22.20
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of Fibrinogen Concentrate as First-line Therapy during Major Aortic Replacement Surgery: A Randomized, Placebo-controlled Trial. https://app.cochat.ai/papers/10.1097/aln.0b013e3182715d4d
- The paper
- Rahe-Meyer, N., Solomon, C., Hanke, A., Schmidt, D. S., Knoerzer, D., Hochleitner, G., Sørensen, B., Hagl, C., & Pichlmaier, M. (2013). Effects of Fibrinogen Concentrate as First-line Therapy during Major Aortic Replacement Surgery: A Randomized, Placebo-controlled Trial. Anesthesiology. https://doi.org/10.1097/aln.0b013e3182715d4d
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.